There are two points of view on the interplay between carotid artery disease and diabetes mellitus: Diabetes mellitus has been recognized as one of the main determinants for the presence and progression of asymptomatic and symptomatic carotid artery disease; and carotid intima-media thickness has been defined as a useful tool for risk stratification of this population.
Hyperglycaemia, duration of diabetes, arterial hypertension, cholesterol and inflammatory markers have previously been determined as independent factors for carotid atherosclerosis in diabetes, and aging as its predictor in this population by our own results. This paper focuses on the particularities of risk factors in diabetic patients (especially in type 2) and evidence-based guidelines for the management and risk reduction of these patients with stroke and/or carotid artery disease.
At present, carotid ultrasound is recommended in diabetic patients with cerebrovascular symptoms. Since the prevalence of diabetes increases constantly, we attempt to address refreshment of criteria for screening of carotid artery disease in the diabetic population. It could be recommended for diabetic patients with at least one more risk factors and for diabetic patients above 60 years of age.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Selby JV Ray GT Zhang D et al. Excess costs of medical care for patients with diabetes in managed care population. Diabetes Care. 1997; 20: 1396-1402. 1b. Berry J Keebler Me McGuire DK. Diabetes Mellitus and Cardiovascular Disease: Pandora's Box has been opened. Herz. 2004; 29(5): 456-62.
2. Kissela BM Khoury J Kleindorfer D et al. Epidemiology of Ischemic Stroke in Patients with Diabetes. The Greater Cincinnati/Northern Kentucky Stroke study. Diabetes care. 2005; 28: 355-359.
2b. Van Wijk I Kappelle LJ van Gijn J Koudstaal PJ Vermeulen G Gorter JW et al. Long-term survival and vascular event risk after transient ischemic attack or minor ischemic stroke: a cohort study. Lancet. 2005; 365(9477): 2098-104.
3. Sacco RL Boden-Albala B Abel G Lin IF Elkind M Hause WA et al. Race-ethnic disparities in in the impact of stroke risk factors in Northern Manhattan Stroke study. Stroke. 2001; 32: 1732-5. 3b. Mallick U Dorobantu M Iqbal B Cheta D. An evidence based approach to the management of cardiovascular disease in Diabetes mellitus. In Cheta D. Vascular Involvment in Diabetes. Carger Basel 2005.
4. Yamanouchi H Shimada H Kuramoto K. Subtypes and proportions of cerebrovascular disease in an autopsy series in a Japanese geriatric hospital. (Tokyo Metropolitan Geriatric Hospital series) Klin Wochenschr. 1990; 68: 1173-7.
5. Hillen T Coshal C Tilling K. on behalf of the South London Stroke register. Cause of stroke recurrence is multifactorial: patterns risk factors and outcome of stroke recurrence: The South London Stroke Register. Stroke. 2003; 34: 1457-63.
6. Kuusisto J Mykkanene L Pyorala K Laakso M. Noninsulin dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke. 1994; 25: 1157-64.
7. Matz K Jeresztes K Tatschl C. Disorders if glucose metabolism in acute stroke patients: an unrecognized problem. Diabetes Care. 2006; 29: 792-7.
8. Karapanaytoides T Piechowsky-Jozwiak B van Melle G. Stroke patterns ethiology and prognosis in patients with diabetes mellitus. Neurology. 2004; 62: 1558-62.
9. Pinto A Tuttolomondo A Di Raimondo D Di Sciacca R Fernandez P Di Gati M et al. A case control study between diabetic and non-diabetic subjects with ischemic stroke. Int J Cardiol. 2008 Apr 25; 125(3):391-6.
10. Shah IM Ghosh SK Collier A. Stroke presentation in Type 2 diabetes and the metabolic syndrome. International Angiology. 2007; 26(01): 26-31.
11. Mohave MR Hashenmazadeh M Jamal MM. Diabetes mellitus is a strong independent risk factor for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005; 105: 315-8.
12. Fonarow GC Srikanthan P. Diabetic cardiomyopathy. Endocrinol Metab Clin North Am. 2006; 35: 575-99.
13. Krahn AD Manfreda J Tate RB Mathewson FA Cuddy TE. The natural history of atrial fibrillation: incidence risk factors and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995; 98: 476-84.
14. Benjamin EJ Levy D Vaziri SM D'Agostino RB Belanger AJ Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994; 271: 840-44.
15. Lammie GA Brannan F Slattery J Warlow C. Nonhypertensive cerebral small vessel disease: an autopsy study. Stroke. 1997; 28: 2222-9.
16. Arauz A Murrillo L Cantu C. Prospective study of single and multiple lacunar infarct using magnetic resonance imaging: risk factors recurrence and outcome in 175 consecutive cases. Stroke. 2003; 34: 2453-8.
17. Rajala U Laakso M Painvansalo M. Blood pressure and atherosclerotic plaques in carotid aortic and femoral arteries in elderly Finns with diabetes mellitus and impaired glucose tolerance. J Hum Hypertension. 2005; 19: 85-91.
18. Henefeld M Koehler C Henkel E Fuecker K Schaper F Temelkova-Kurtschiev T. Postchallenge hyperglycemia relates more strongly than fasting hyperglycemia with carotid intima-media thickness: the RIAD study Diabetic Med. 2000; 17: 835-40.
19. Hancu N Cerghizam A. Global approach to Cardiovascular Risk in Type 2 Diabetic Persons. In: Hancu N. Cardiovascular Risk in Type 2 Diabetes mellitus. Springer Verlag Berlin Heidelberg New York. 2003: 240-76. 19b. Brohall G Behre CJ Hulthe J Wikstrand J Fagerberg B. Prevalence of diabetes mellitus and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care. 2006; 29: 363-7.
20. 1 IRAS 2 Kieschl S Willeit J for Bruneck Study Group. The natural course of atherosclerosis part 1: incidence and progression. Arteriosc Thromb Vasc Biol. 1999; 34: 1484-90.
21. Selvin E Coresh J Golden SH. Glycemic control Atherosclerosis and Risk factors for cardiovascular Disease in Type 2 Diabetes. The Atherosclerosis Risk in Comunities Study. Diabetes Care. 2005; 28: 1963-75.
22. Göksan B Erkol G Bozluolcay M Ince B. Diabetes as a determinant of high-grade carotid artery stenosis: Evaluation of 1058 cases by Doppler sonography. J Stroke Cerebrovasc Dis. 2001; 10(6): 252-6.
23. Yang B Li TD Wang JS Zhi G Jin WS Xu Y. Insulin resistance and carotid atherosclerosis in 221 patients with potentional hyperglycemia. Chin Med Sci. 2005; 20(2): 108-11.
24. Baldassarre D de Jong A Amato M Werba PJ Castelnuovo S Frigerio B et al. Carotid intima-media thickness and markers of inflammation endothelial damage and hemostasis. Ann Med. 2007; 1-24.
25. Wang JG Staessen JA Li Y Van Bortel LM Nawrot T Fagard R. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Ca antagonist and ACE reduce IMT. Stroke. 2006 Jul; 37(7): 1933-40.
26. Williams R Aiery M. Epidemiology and pathogenesis of diabetic angiopathy. In: Tooke J. Diabetic angiopathy. Arnold 1999.
27. Ford ES Giles WH Dietz WH. Prevalence of the Metabolic Syndrome Among US Adults. JAMA 2002; 287: 356-9.
28. Pollex R Al-Shalli KZ House AA. Relationship of metabolic syndrome to carotid ultrasound traits. Cardiovascular Ultrasound. 2006; 4: 28-35.
29. Lu W Resnick HE Jablonski KA et al. Non-HDL Cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care. 2003; 26: 16-23.
30. Jiang R Schulze M Li Tricia et al. Non-HDL Cholesterol and Apoplipoprotein B Predict Cardiovascular Disease Events Among Men With Type 2 Diabetes. Diabetes Care; 2004: 27: 1991-7.
31. De Vries R Perton GF Dallinga-Thie GM. Plasma cholesterol ester transfer is a determinant of intimamedia thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes. 2005; 54(12): 3554-9.
32. Kawamoto R Tomita H Oka Y Kodama A Kamitami A. Metabolic syndrome amplifies the LDL-cholesterol associated increases in carotid atherosclerosis. Intern Med. 2005; 44(12): 1232-8.
33. Hulthe J Bokemartk L Wikstrand J et al. The metabolic syndrome LDL particle size and atherosclerosis: The AIR study. Arterioscler Thromb Vasc Biol. 2000; 20: 2140-7.
34. Rajala U Laakso M Paivansalo M. Low insulin sensitivity measured by both quantitative insulin sensitive check index and homeostasis model assessment method as a risk factor of increased intima-media thickness of the carotid artery. J Clin Endocrinol Metab. 2002; 87: 5092-7.
35. Szernichow S Bertrais S Oppert JM Galan P Blacher J Ducimetiere P et al. Body composition and after repartition in relation to structure and function of a large arteries in middle-aged adults (the SU.VI.MAX study). Int J Obes. 2005; 29: 826-32.
36. Nomura M Kasamai R Ohashi M Ymada Y Abe. H. Significantly higher invcidence of carotid atheroscelrotiss found in japanese type 2 diabetic patients with early nephropathy. Diabetes Res Clin Pract. 2004; 66(1): 161-3.
37. Zhang L Zhao F Yang Y Qi L Zhang B Wang F et al. Association between carotid artery intimamedia thickness and early-stage CKD in a Chinese population. Am J Kidney Dis. 2007; 49(6): 786-92.
38. Tuimlehto J Rastenyete D Jousilahti P Sarti C Vartianinen E. Diabetes mellitus as a risk factor for death from stroke: prospective study of the middleaged Finnish population. Stroke. 1996; 27: 210-5.
39. Folsom AR Rasmunssen ML Chambles ME. Prospective associations of fasting insulin body fat distribution and diabetes with risk of ishaemic stroke. ARIC study. Diabetes Care. 1999; 22: 1077-83.
40. Megherbi SA Mialn C Minier D et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke. Data from from the European BIOMED Stroke project. Stroke. 2003; 344: 688-94.
41. Bonora E Kiechl E Oberhollenzer F. Imparied glucose tolerance Type 2 diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study. Diabetologia. 2000; 43: 156-64.
42. Grag R Chaudhuri A Munscauer F. Hyperglycemia insulin and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke. 20006; 37: 267-73.
43. Selvin E Coresh J Golden SH. Glycemic control Atherosclerosis and Risk factors for cardiovascular Disease in Type 2 Diabetes. The Atherosclerosis Risk in Communities.
44. Jorgensen H Nkayama H Raaschou HO Olsen TS Stroke in patients with diabetes. The Copenhagen Stroke Study. Stroke. 1994; 25: 1977-84.
45. Lithner F Asplund K Eriksson S Haag E Strand T Wester PO. Clinical characteristics on diabetic stroke patients. Diab Metab. 1988; 14: 15-19.
46. Toni D Sacchetii Ml Argentino C Gentile M Cavalleti C Frontoni M et al. Does hyperglycemia play a role on the outcome of ishemic stroke patients? J Neurol. 1992; 239: 382-6.
47. Kiers L Davis SM Larkins R Hopper J Tress B Rossiter SC et al. Stroke topography and outcome in relation to hyperglicaemia and diabetes. J Neurol Neurosurg Psychiatry. 1992; 55: 263-70.
48. Pulsinelli WA Levy DE Sigsvee B Scherer P Plum F. Increased damage after ischemic stroke in patients with hyperglicaemia with or without established diabetes mellitus. Am J Med. 1983; 74: 540-4.
49. Peila R Rodriquez BL Launer LI. Type 2 diabetes APOE Gene and the risk for Dementia and related pathologies. Honolulu Asia-Aging study. Diabetes. 2002; 52: 1256-62.
50. Korf ESC White LR Scheltens P Launer LJ. Brain Aging in Very old men with type 2 diabetes. Diabetes Care. 2006; 29(10): 2268-74.
51. Albers GW Dalen JE Laupacis A. Antithrombotic therapy in atrial fibrillation. Chest. 2001; 119; 1945- 2065.
52. Fuster V Ryden LE Asinger RW Cannon DS Crijns HJ Frye RL et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J. 2006; 27: 1979-2030.
53. Gage BF Waterman AD Shannon W. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864-70.
54. Wang TJ Massaro JM Levy D. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003; 290: 1049-1056.
55. Adler A Stratton I Neil H. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000; 321: 17: 412-9.
56. Chalmers J Joshi R Patel A. Advances in reducing the burden of vascular disease in type 2 diabetes. Clin Exp Pharmacol Physiol. 2008 Apr; 35(4): 434-7.
57. Tuomilehto J Rastenyte D Birkenhager WH. Effects of calcium-channel blockade on older patients with diabetes and systolic hypertension. (Syst-Eur). N Engl J Med. 1999; 340: 677-84.
59. The Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology and of the European Association of the Study of Diabetes. doi.10.1093/eurheartj/ehl261.
60. Khan NA Hemmelgarn B Herman RJ Rabkin SW McAlister FA Bell CM et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol. 2008; 24(6): 465-75.
61. Kawamura T. Cerebrovascular disease and diabetic patients with hypertension. Nippon Rinsho. 2003 Jul; 61(7): 1175-80.
62. Hirsh J Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med. 2004; 164: 2106-10.
63. Bosevski M Georgievska Lj Borozanov V. Dual antithrombotic therapy and hypercoagulability in diabetic patients. Am Heart J. 2008; 155(6): e47.
64. Serebruany VL Malinin AI Pokov A Barsness G Hanley DF. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. Am Heart J. 2008 Jan; 155(1): 93.e1-7.
65. Williams LS Rotich J Qi R Fineberg N Espay N Bruno A et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 200259; 67-71 x 68. UKPDS 33. Lancet. 1998; 352: 837-53.
66. Diabetes Prevention Research Programme. reduction in the incidence of type 2 diabetes with lifestyle modification and or metformin. N Engl J Med. 2002; 346: 394-46.
67. Heart protection study Collaboration Group. MRC/BHF Heart Protection Study of cholesterollowering in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003; 361: 2005-16. 67b. Chambers BR Roberts NG. Asymptomatic carotid artery stenosis. Current Treatment in Cardiovascular Medicine. 2007; 9(2): 81-89.
68. Eton D. Surgery and Medical Management of Cerebrovascular Disease in: Eton D. Vascular Disease: A Multi-Specialty approach to Diagnosis and Management Landes Bioscience Austin 1999.
69. Reina-Gutierrez T Serrano-Hernanado FJ Sanchez- Hervas L. Recurrent carotid artery stenosis following up endarterectomy: natural history and risk factors. Euro J Vasc Endovasc Surg. 2005; 29(4): 334-41.
70. Tropeano AI Boutouyrie P Katsahian S. Glucose level is a major determinant of carotid intima-media thickness in patients with hypertension and hyperglycemia. J Hypertension. 2004; 22(11): 2153-60.
71. Levy EI Mocco J Samuelson RM Ecker RD Jahromi BS Hopkins N. Optimal treatment of carotid artery disease. JACC 2008; 51(10): 979-985.
73. Coward Lj Featherstone RL Brown MM. Safety and efficacy of endovascular treatment of carotid treatment of carotid artery stenosis compared with carotid endarterectomy: a Cochrane systematic review of the randomized evidence. Stroke. 2005; 36: 905-11.
74. Hancu N Cerghizan Cornelia B. Practical approach to the multifactorial risk in type 2 diabetes. In Cheta D. Multivacsular involvement in Diabetes. Karger Basel 2005.
75. Stevens RJ Kothari V Adler AI Stratton IM Holman RR on behalf of the UKPDS Group. The UKPDS risk engine: a model for the risk the coronary heart disease in type 2 diabetes (UKPDS 56). Clinical Science. 2001; 101: 671-9.
76. Kothari V Stevens RJ Adler AJ Stratton IM Manley SE Neil A Holman RR for the UKPDS Group (UKPDS 60) Risk for stroke in the 2 diabetes estimated by UKPDS risk engine. Stroke. 2002; 33: 776-1781.
77. Song SH Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabetic Medicine. 2003; 21: 238-245.
79. Haffner SM Lehot S Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229-34.
80. Doney A Lee S Leese G Morris A Palmer C. Increased Cardiovascular Morbidity and Mortality in Type 2 Diabetes Is Associated With Glutathione S Transferase Theta-Null Genotype (A Go-DARTS Study). Circulation. 2005; 111: 677-88.
81. Morrish NJ Steven LK Head J et al. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO multinational study of vascular disease in diabetics) Diabetologia. 1990 33: 542-8.
82. Saydah SH Fradkin J Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291(3): 335-42.
83. Orchard TJ Strandness DE Jr. Assessment of peripheral vascular disease in diabetes. Report and recommendations of an international workshop sponsored by the American Heart Association and the American Diabetes Association Diabetes Care. 1993 Aug; 16(8): 1199-209.
84. De Angelis M Scrucca L Leandri M et al. Prevalence of carotid stenosis in type 2 diabetic patients asymptomatic for cerebrovascular disease. Diabetes Nutr Metab. 2003 Feb; 16(1): 48-55. 84b. Lacroix P Aboyans V Criqui MH Bertin F Bouhamed T Archambeaud F Laskar M. Type 2 diabetes and carotid stenosis: a proposal for a screening strategy in asymptomatic patients. Vascular Medicine. 2006; 11: 93-99.
85. Lorenz MW Markus HS Bots MI et al. prediction of Clinical Cardiovascular Events with Carotid Intima- Media Thickness. Circulation. 2007; 115: 459- 467.
86. Duval M Altman JJ. When should ultrasonography be used to detect asymptomatic carotid atheroma in diabetic patients? Diabetes Metab. 2006 Dec; 32(6): 638-42. 86b. Bosevski M Borozanov V Vavlukis M Pemovska G Georgievska-Ismail Lj. Carotid ultrasound blood lipids and waist determination can predict a future coronary revascularisation in the type 2 diabetic cohort. Prilozi. 2007; 28(2): 127-36.
87. Bernard S Serusclar A Targe F et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects. Diabetes Care. 2005; 28(5): 1158-9.
88. Parikh A Daneman D. Is Carotid Ultrasound a Useful Tool in Assessing Cardiovascular Disease in Individuals with Diabetes? Diabetes Technology & Therapeutics. 2004; 6(1): 65-9.
89. Yokoyama H Katakami N Yamasaki Y. Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke. 2006; 37(9): 2420-7.
90. Bots ML Evans GW Riley WA Grobbe DE. Carotid intima-media thickness Measurements in Intervention studies. Stroke. 2003; 34: 2985-94.
91. Spence JD. Ultrasound measurements of carotid plaques as a surrogate outcome for coronary artery disease. Am J Cardiol. 2002; 89 (suppl): 10B-16B.
92. Giral P Brucket E Daiorrou F. Usefulness in predictting coronary artery disease by ultrasonic evaluation of the carotid arteries in asymptomatic hypercholesterolemic patients with positive exercise stress test. Am J Cardiol. 1999; 84: 14-17.
93. Lee EJ Kim HJ Bae JM et al. Relevance of common carotid intima-media thickness and carotid plaque as risk factors for ischemic stroke in patients with type 2 diabetes mellitus. Am J Neuroradiol. 2007; 28(5): 916-9.
94. Giral P Brucket E Daiorrou F. Usefulness in predicting coronary artery disease by ultrasonic evaluation of the carotid arteries in asymptomatic hypercholesterolemic patients with positive exercise stress test. Am J Cardiol. 1999; 84: 14-17.
95. Lorenz M Markus H Bots M Rosval M Sitzer M. Prediction of Clinical Cardiovascular Events with Carotid Intima-media thickness: A systematic review and Meta-analysis. Circulation. 2007; 115: 459-67. 95b. De Angelis M Strucca L Leandri M. Prevalence of carotis stenosis in type 2 diabetic pts asymptomatic for cerebrovascular disease. Diabetes Nutr Metab. 2003; 16: 48-55.
96. Bosevski M Influence of metabolic risk factors for presence of carotid artery disease in patients with type 2 diabetes and coronary artery disease. Diab Vasc Dis Res. 2007; 4(1): 49-52.
97. Lacroix P Aboyans V Criqui MH Bertin F Bouhamed T Archambeaud F Laskar M. Type-2 diabetes and carotid stenosis: a proposal for a screening strategy in asymptomatic patients. Vasc Med. 2006; 11(2): 93-9.
98. Parikh A Daneman D. Is Carotid Ultrasound a Useful Tool in Assessing Cardiovascular Disease in Individuals with Diabetes? Diabetes Technology & Therapeutics. 2004; 6(1): 65-9.
99. Bosevski M Peovska I Georgievska-Ismail L. Noninvasive imaging of diabetic vascular disease. Review in Cardiovascular Medicine 2008; Fall (in press)
100. Ragi P Bellasi A Ratti C. Ischemia Imaging and Plaque Imaging in Diabetes. Diabetes Care. 28: 2787-2794 2005.
101. Charvat J Michalova K Chlumsky J Horácková M Valenta Z Zdárska D. The significance of carotid artery plaques in the detection of coronary artery disease in asymptomatic type 2 diabetic patients. J Int Med Res. 2006; 34(1): 13-20.
102. Mudríková T Szabová E Tkác I. Carotid intimamedia thickness in relation to macrovascular disease in patients with type 2 diabetes mellitus. Wien Klin Wochenschr. 2000; 112(20): 887-91.
103. Bernard S Sérusclat A Targe F Charrière S Roth O Beaune J et al. Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects. Diabetes Care. 2005; 28(5): 1158-62.
104. Kitagawa K Hougaku H Yamagami H Hashimoto H Itoh T Shimizu Y et al. for OSACA2 Study Group. Carotid intima-media thickness and risk of cardiovascular events in high-risk patients. Results of the Osaka Follow-Up Study for Carotid Atherosclerosis 2 (OSACA2 Study). Cerebrovasc Dis. 2007; 24(1): 35-42.
105. Brohall G Oden A Fagerberg B. Carotid artery intima-media thickness in patients with type 2 diabetes mellitus and impaired glucose tolerance: a systemic review. Diabetic Medicine. 2005; 23: 609-616.
106. Hodis HM Mack WJ LaBree L Seizer RH Liu CH Azen SR. The role of carotid intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998; 128: 262-9.
107. Yamasaki Y Kodama M Nishizawa H Sakamoto K Matsuhisa M Kajimoto Y et al. Carotid Intima- Media thickness in Japanese Type 2 Diabetic Subjects. Predictors of progression and relationship with incident coronary heart disease. Diabetes Care. 2000; 23(9): 1310-5.
108. Salonen R Nyyssonen K Porkkala E. Kuopio Atherocslerosis Prevention Study (KAPS). A population- based primary preventive trial of the effect of LDL lowering in atherosclerotic progression in carotid and femoral arteries. Circulation. 1995; 92: 1758- 64.
109. Chambless LE Folsom AR Davis V Sharett R Heiss C Sortlie P et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study 1979-1998. Am J Epidemiol. 2002; 155: 38-47.
110. Zuriek M Touboul PJ Bonithon-Kopp C Courbon D Berr C Leroux C Ducimetiere P. Cross sectional and 4-year longitudinal associations between brachial pulse pressure and common carotid intimae-media thickness in a general population. The EVA study. Stroke. 2002; 33: 550-5.
111. Mackinnon AD Jerrard Dune P Sitzer M Biehler A von Kegler S Markus HS. Rates and determinants of site-specific progression of carotid intima-media thickness: the carotid atherosclerosis progression study (CAPS). Stroke. 2004; 35: 2150-4.
112. Go AS Hylek EM Phillips KA Chang Y Henaulst LE Selby JV Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-75.
113. AF Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from the randomized controlled trials. Arch Intern Med. 1994; 154: 1449-57.
114. Korf ES White LR Scheltens P Launer LJ. Brain aging in very old men with type 2 diabetes: the Honolulu- Asia Aging Study. Diabetes. 2006; 29(10): 2268-74.
115. Girdia Cb Avogaro A Maggini M Lombardo F Mannuci E Turco S et al. Incidence and risk factors for stroke in type 2 diabetes. Stroke. 2007; 38: 1154- 60.
116. Schram MT Kostense PJ Van Dijk RA Dekker JM Nijpels G Bouter LM et al. Diabetes pulse pressure and cardiovascular mortality: the Hoorn Study. J Hypertens. 2002; 20(9): 1743-51.
117. Hendbald B Nilsson P Janzon L Berglund G. Relation between insulin resistance and carotid intiamedia thickness and stenosis in non-diabetic subjects. Results from a cross sectional study in Malmo. Sweden. Diabet Med. 2000; 17: 299-307.
118. Brohall G Oden A Fagberg B. Carotid artery intima- media thickness in patients with type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabetic Medicine. 2005; 23: 609-16. 118b. Najjar SS Scuteri A Lakatta EG. Arterial aging. Is it an immutable ardiovascular risk factor? Hypertension. 2005; 46: 454-462.
119. Zunker P Sxhick A Buschmann HC Georgiadis D Nabavi D Edelmann M et al. Hyperinsulinism and cerebral microangiopathy. Stroke. 1996; 27: 219-23.
120. Mast H Thompson JL Lee Sh Mohr JR Sacco RL. Hypertension and diabetes mellitus as determinants for multiple lacunar infarcts. Stroke. 1995; 26: 30-3.